Weekly issue 2026-W41 ·
RhoA through its various effectors mediate mitochondrial fragmentation in polycystic kidney disease
Plain language
Mitochondria are the parts of a cell that make energy. In PKD they tend to break into small pieces, and this study looked at why. In kidney cells that had lost the PKD proteins, a switch-like protein called RhoA drove this breaking up. Blocking RhoA, or the proteins it acts through, prevented or reversed it, including in cells from people with PKD. The broken-up mitochondria also encouraged scarring processes. This is laboratory research on cells; no treatment based on it exists yet.
Clinical note
Mechanistic cell study. RhoA activation alone induced DRP1-mediated mitochondrial fission in tubular cells. Genetic or pharmacological inhibition of RhoA or its effectors (ROCK/LIM kinase/cofilin, phospho-myosin or formins) prevented or reversed PC1/PC2 loss-induced fragmentation; formin-driven fragmentation required F-actin polymerising capacity but not binding to INF2. PC1 re-expression or RhoA/effector inhibition restored mitochondrial morphology in human PKD cells, and fragmentation facilitated fibrogenesis. Positions RhoA-mediated actin polymerisation and myosin activation as a central mechanism of PKD-associated mitochondrial fragmentation. Cell-based data only.
Question for your next visit
How do researchers decide which laboratory findings are worth testing as treatments for PKD?